Company news
Agenus Inc. news in 2025
Agenus Inc.'s news releases, calls and decks from 2025, newest first.
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
December 23, 2025
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
November 19, 2025
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
November 18, 2025
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
November 10, 2025
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
November 5, 2025
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
October 17, 2025
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
October 16, 2025
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
September 9, 2025
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 5, 2025
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
August 26, 2025
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
August 19, 2025
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
August 11, 2025
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
July 31, 2025
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
July 25, 2025
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
July 6, 2025
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
June 17, 2025
Agenus Announces Virtual Annual Shareholders Meeting
June 10, 2025
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
June 3, 2025
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
May 30, 2025
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
May 15, 2025
Agenus Reports Q1 2025 Financial Results and Key Business Updates
May 12, 2025
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
May 12, 2025
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
April 29, 2025
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
April 28, 2025
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
April 25, 2025
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
April 23, 2025
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
March 25, 2025
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
March 19, 2025
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
March 11, 2025
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
February 26, 2025
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
February 25, 2025
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
February 25, 2025
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
February 24, 2025
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
February 23, 2025
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
January 28, 2025
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
January 21, 2025